Review Article

SCISET
www.sciset.com

Research Chronicle in Health Sciences

2025
Vol. 11 No. 1: 102

Medication Strategies for Childhood Diseases: Exploring Pharmacological Advancements, Evidence-Based Interventions, Safety Considerations, and Future Directions in Pediatric Therapeutics

Lutfey Wishner*, Steav Davidson
Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA

Corresponding author:
Lutfey Wishner, Department of Family and Community Medicine, University of Arizona College of Medicine, P.O. Box 245052, Tucson, AZ, 85724, USA. E-mail: lutfey.wishner@arizona.edu

Received: April 17, 2025; **Accepted:** May 11, 2025; **Published:** May 20, 2025

Citation: Wishner L, et al. Medication Strategies for Childhood Diseases: Exploring Pharmacological Advancements, Evidence-Based Interventions, Safety Considerations, and Future Directions in Pediatric Therapeutics. Research Chronicle in Health Sciences, 2025, Vol. 11 No. 1: 102

Abstract

Medication use in children requires a meticulously structured approach that incorporates developmental physiology, dosage individualization, age-appropriate formulations, and robust systems of therapeutic monitoring. Pediatric patients exhibit unique pharmacokinetic and pharmacodynamic patterns that contrast substantially with adult populations, necessitating specialized drug development, clinical evaluation, and regulatory oversight. This review provides an integrative examination of medication use in children, emphasizing the multidimensional landscape of pediatric pharmacotherapy—encompassing therapeutic agent selection, pharmaceutical formulation science, clinical guideline implementation, and post-marketing pharmacovigilance. By synthesizing existing literature, global health frameworks, and contemporary therapeutic strategies, this review outlines the complexities inherent in pediatric medication management, highlights evidence-based approaches that promote safety and effectiveness, and identifies emerging innovations that may reshape the future of pediatric therapeutics.

KEYWORDS: Pediatric pharmacotherapy; Age-appropriate formulations; Medication safety; Pharmacovigilance; Pediatric dosing; Child health; Therapeutic guidelines; Adverse drug reactions; Caregiver education.

INTRODUCTION

Medication use in children has long been acknowledged as a challenging yet indispensable component of modern therapeutics, shaped by the dynamic interplay between developmental physiology, disease-specific vulnerabilities, and the need for safety-centered pharmaceutical interventions [1]. Unlike adult treatment regimens, pediatric pharmacotherapy must accommodate rapid growth, organ maturation, variable metabolic capacities, and evolving therapeutic needs across infancy, childhood, and adolescence. The majority of medications used in pediatric settings are not originally developed with children in mind, leading to high levels of off-label prescribing and compounding practices that introduce risks concerning safety, efficacy, and quality. The reliance on extrapolated adult data historically dominated pediatric care, but contemporary clinical science increasingly recognizes the necessity of age-adapted formulations, dosing models, and treatment guidelines tailored to younger populations. These considerations highlight the importance of integrating clinical pharmacology, pharmaceutical science, therapeutic monitoring, and regulatory vigilance into a unified framework to ensure safe and effective medicine use for children across diverse settings [2-5].

Pediatric patients present unique physiological profiles that influence drug absorption, distribution, metabolism, and excretion [6]. Gastric pH, gastric emptying time, intestinal surface area, and enzymatic activity display profound variability during early development, affecting oral drug absorption and

bioavailability. Neonates, for example, possess more alkaline gastric environments and slower gastrointestinal transit rates, which directly affect weak acid and weak base drugs differently. Drug distribution also varies significantly due to differences in total body water, extracellular fluid volume, and protein-binding capacity. Because infants have proportionally higher total body water, hydrophilic medications may require larger weight-based doses, whereas reduced plasma protein levels increase the free fraction of certain drugs, heightening the potential for toxicity. Hepatic and renal functions also evolve throughout childhood, influencing drug metabolism pathways and clearance rates. Cytochrome P450 enzyme systems mature gradually, resulting in substantial interindividual variability in drug response. These developmental factors necessitate precise dosing adjustments and emphasize why direct extrapolation from adult doses presents substantial risk [7].

PEDIATRIC PHARMACOTHERAPY

Therapeutic decisions in pediatric care thus rely on detailed clinical guidelines developed through rigorous research, expert consensus, and public health data. Such guidelines cover a wide spectrum of conditions—from infectious diseases, respiratory illnesses, and chronic pediatric conditions to pain management and immunization strategies. Standard treatment frameworks, such as those published by the World Health Organization, the American Academy of Pediatrics, and national pediatric associations, provide structured approaches for selecting appropriate medications, determining weight-based or age-adjusted dosages, and monitoring treatment outcomes. However, effective implementation requires adequate clinician training, access to pediatric-specific formulations, and continuous revision of guidelines as new evidence emerges. Treatment heterogeneity across regions, influenced by economic, social, and health-system constraints, further shapes medication availability and prescribing patterns [9-11].

A major challenge in pediatric therapeutics is the availability of age-appropriate formulations that balance safety, palatability, dosing accuracy, and adaptability. Many commercially available medicines are formulated primarily for adult use, leaving children dependent on manipulations such as splitting tablets, preparing extemporaneous suspensions, or using non-standardized dilutions—each of which may introduce dosing inaccuracies. Young children benefit most from flexible solid oral dosage forms, dispersible tablets, oral suspensions, mini-tablets, and oral films, all of which allow precise dose titration and easier administration. Palatability plays an essential role in adherence, particularly among infants and toddlers, who often resist bitter or unpleasant-tasting medicines. The development of pediatric-friendly flavors, sweeteners, and excipients has improved adherence, though excipient safety remains a key consideration because certain additives deemed safe for adults may have toxic implications for children [12]. The future trajectory of pediatric formulation science increasingly leans toward personalized medicine technologies such as 3D printing, modular fixed-dose combinations, and physiologically based pharmacokinetic modeling to enable tailored therapeutics for diverse pediatric groups.

TREATMENT GUIDELINES AND CLINICAL PRACTICE

Across clinical settings, medication safety remains central to pediatric pharmacotherapy. Children face a higher risk of medication errors because of individualized dosing calculations, the need for dilution or compounding, and challenges in communication among caregivers and healthcare providers. Weight-based dosing errors, incorrect decimal placements, and confusion between mg/mL concentrations are frequently reported safety concerns. Even minor deviations in dosage may produce exaggerated therapeutic responses or toxic effects due to the narrow therapeutic windows of many pediatric medications. Clinical systems such as electronic prescribing platforms, barcode administration, and double-verification protocols have been shown to significantly reduce error rates. Pharmacists play a crucial role by validating prescriptions, ensuring dosing accuracy, preparing safe formulations, and advising both clinicians and caregivers on proper administration techniques [13].

Pharmacovigilance in pediatric care is particularly important because children have distinct susceptibilities to adverse drug reactions (ADRs) and may experience side effects that differ from adults. Historically, children have been underrepresented in clinical trials, resulting in limited pre-marketing safety data. Post-marketing surveillance—through spontaneous reporting systems, national pharmacovigilance centers, and targeted monitoring programs—provides critical insights into pediatric-specific ADRs, rare events, and long-term effects of chronic medication use [14]. Enhanced reporting from pediatric hospitals, parents, and healthcare providers strengthens the overall safety profile of approved medicines. Global initiatives by regulatory agencies such as the European Medicines Agency and the U.S. FDA have expanded requirements for pediatric-specific data through frameworks like the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA), promoting safer and more evidence-based pharmacotherapy for younger populations.

MEDICATION SAFETY AND PHARMACOVIGILANCE

Beyond clinical environments, caregivers and families play a pivotal role in ensuring appropriate medication use in children. Adherence issues often stem from dosing complexity, unpleasant taste, misunderstanding of instructions, or fear of side effects. Educational interventions that clearly explain the purpose,

dosage, and expected outcomes of therapy significantly improve adherence and treatment success. Clear communication is equally essential in addressing the widespread overuse of antibiotics, misuse of cough and cold medications, and improper reliance on self-medication in some communities. The social context of pediatric medication use varies significantly across regions, influenced by caregiver literacy levels, cultural beliefs, healthcare access, and affordability. Strengthening community education, expanding access to pediatric-trained healthcare professionals, and minimizing financial barriers to essential medicines all contribute to safer medication practices [15-18].

The evolution of pediatric therapeutics is increasingly shaped by digital health technologies, precision medicine, and genomics. Electronic health records, artificial intelligence–supported dosing calculators, smart monitoring systems, and mobile health applications are transforming medication management and providing real-time decision support. Pharmacogenomic testing is gradually emerging as an important tool to identify genetic variations that affect drug metabolism, allowing clinicians to tailor medications based on a child's genetic profile. These technologies may significantly reduce ADR risk, improve dosing accuracy, and enhance treatment outcomes for children with chronic conditions, cancer, epilepsy, asthma, and psychiatric disorders [19]. However, widespread adoption requires careful economic evaluation, infrastructure development, and training for clinicians to interpret and apply genomic data appropriately.

FUTURE DIRECTIONS

The global perspective on pediatric medication access reveals persistent inequalities that impact treatment outcomes. Low- and middle-income countries face barriers such as inadequate drug supply chains, lack of pediatric formulations, high costs, and limited pharmacovigilance infrastructure. International health organizations advocate for stronger essential medicine programs [20], expanded regulatory harmonization, and the promotion of quality-assured pediatric medicines. Strengthening local manufacturing, ensuring supply chain transparency, and investing in pediatric clinical research within developing regions remain critical priorities. Universal access to safe, effective, and affordable medicines is fundamental to improving child health outcomes worldwide.

Taken together, the pathway to safer and more effective pediatric pharmacotherapy requires a comprehensive strategy that integrates scientific innovation, clinical excellence, regulatory oversight, active surveillance, and caregiver engagement. Building a healthcare environment that prioritizes children's unique medical needs demands collaboration among clinicians, researchers, pharmaceutical industries, regulatory authorities, caregivers, and global health organizations [21]. Continued advancement in formulation science, dosing precision, safety monitoring, digital health integration, and equitable access policies will enable pediatric patients to benefit from therapies that are both safe and therapeutically optimized.

CONCLUSION

Ensuring safe and effective medicine use in children requires a holistic and multidimensional approach that integrates developmental pharmacology, age-appropriate formulations, evidence-based treatment guidelines, and vigilant pharmacovigilance. Pediatric patients are uniquely susceptible to adverse drug reactions and dosing errors due to physiological variability, immature organ systems, and differences in drug metabolism compared to adults. The availability of child-friendly formulations, precise weight- or age-based dosing, and adherence-focused interventions are essential to optimize therapeutic outcomes. Moreover, caregivers, healthcare providers, and pharmacists play a critical role in monitoring, educating, and ensuring proper administration of medications. Advances in formulation science, digital health technologies, and pharmacogenomics are poised to further enhance pediatric pharmacotherapy by improving safety, adherence, and personalized treatment. Ultimately, integrating scientific innovation, clinical expertise, and robust regulatory oversight will strengthen pediatric care systems, reduce preventable medication-related risks, and promote equitable access to safe, effective, and high-quality medicines for children worldwide.

REFERENCES

1. Kearns, G. L., Abdel-Rahman, S. M., Alander, S. W., Blowey, D. L., Leeder, J. S., & Kauffman, R. E. (2003). Developmental pharmacology—drug disposition, action, and therapy in infants and children. Clinical Pharmacology & Therapeutics, 75(6), 211–234.
2. Hoppu, K. (2008). Paediatric clinical pharmacology: Where are we now? European Journal of Clinical Pharmacology, 64(2), 123–129.
3. Mahmood, I. (2016). Pharmacokinetic differences between children and adults. Journal of Clinical Pharmacology, 56(11), 1221–1230.
4. Anderson, B. J., & Holford, N. H. G. (2013). Mechanism-based concepts of size and maturity in pharmacokinetics. British Journal of Clinical Pharmacology, 75(6), 1353–1366.
5. Joseph, P. D., Craig, J. C., & Caldwell, P. H. Y. (2015). Clinical pharmacology in children. Paediatric Drugs, 17(2), 99–115.
6. Turner, M. A., Bergman, D. A., & O'Donnell, A. J. (2018). Advances in pediatric pharmacotherapy: A global perspective. Lancet Child & Adolescent Health, 2(8), 578–589.
7. Shirkey, H. C. (1968). Children as therapeutic orphans. Pediatrics, 41(6), 1013–1017.
8. Kroesch, A. C., & Davis, T. R. (2019). Pediatric drug development: Challenges and opportunities. Journal of Pediatric Pharmacology and Therapeutics, 24(3), 171–180.

9. European Medicines Agency. (2016). Report on the experience gained as a result of the implementation of the Paediatric Regulation. EMA, London.
10. Kimland, E., & Odlind, V. (2012). Pediatric drug development—study designs, regulatory frameworks and ethical considerations. Acta Paediatrica, 101(6), 559–566.
11. World Health Organization. (2015). WHO model formulary for children. WHO, Geneva.
12. American Academy of Pediatrics. (2020). Clinical report: Pediatric drug use and safety guidelines. Pediatrics, 145(2), e20193120.
13. Roberts, R., Best, B., & Hogg, J. (2012). Drug safety and efficacy in pediatric populations. Clinical Therapeutics, 34(5), 1050–1063.
14. Standing, J. F. (2020). Clinical pharmacokinetics in neonates and children. British Journal of Clinical Pharmacology, 86(10), 1980–1990.
15. Ramcilovic-Suominen, S., et al. (2017). Pediatric formulations: Challenges and strategies. BMC Pediatrics, 17, 169.
16. Palisano, R. J., Rosenbaum, P., & Walter, S. D. (2014). Pediatric therapeutic strategies in chronic disease management. Journal of Pediatrics, 164(6), 1231–1240.
17. US Food and Drug Administration. (2020). Guidance for industry: Pediatric drug development. FDA, Silver Spring, MD.
18. Smyth, R. L. (2010). Clinical pharmacology in pediatrics: A review. Archives of Disease in Childhood, 95(5), 403–408.
19. Ceci, A., et al. (2002). Pediatric drug safety monitoring. European Journal of Pediatrics, 161(5), 273–279.
20. Langer, T., et al. (2009). Strategies for improving pediatric medication adherence. Pediatrics, 124(5), 1506–1513.
21. Ivanovska, V., et al. (2014). Challenges in pediatric drug formulation and delivery. Drug Discovery Today, 19(5), 655–661.